Prices delayed by 15 minutes
Next earnings report: 29 October 2026 · Earnings calendar
The series is stated in the current share scale after splits; dividends are not included in the price
Illumina, Inc. trades on Nasdaq under the ticker ILMN. The company belongs to the Health care sector. The trading history on this page starts on 22 August 2016.
Over the past 52 weeks ILMN has traded between 88.00 $ and 309.35 $. As of 09 October 2026 the price stood 79.77 % of the way from the 52-week low to the high.
Over one year ILMN shares rose 173.66 %; over six months they rose 113.93 %. Volatility over 90 days is 48.09 %. Dividends are not included: this is price change only, as of 09 October 2026.
ILMN trades at a price-to-earnings ratio of 47.5, above the sector median of 24.8. Price to sales is 9.2, above the sector median of 3.9. Price to book is 15.1, above the sector median of 2.4. Calculated from reports for the period ending 31 March 2026.
| Date | Open | High | Low | Close | Volume, shares |
|---|---|---|---|---|---|
| 08 October 2026 | 263.69 | 266.14 | 254.00 | 264.57 | 3M |
| 07 October 2026 | 271.21 | 276.20 | 260.45 | 267.76 | 3M |
| 06 October 2026 | 301.58 | 309.35 | 271.55 | 273.54 | 4M |
| 05 October 2026 | 273.00 | 296.25 |
Based on the last 12 months of reports, through 31 March 2026
The sector median covers every company in the sector on the US market, loss-making ones included.
Illumina makes machines that read DNA — nearly all the world's genome sequencing runs on its instruments.
The instrument-and-consumable model: a sequencer sits in a laboratory for years while reagents and flow cells are bought for every run. Consumables supply most of the revenue at high margins, so what matters is not machine sales but how much research is run on the installed base.
The company spent several years dealing with the consequences of buying a blood-based cancer test developer: regulators on both continents blocked the deal and forced it to be unwound. Growth now runs into the budgets of research institutions and biotech start-ups, and into competitors arriving with platforms of their own. The company pays no dividend.
Address:5200 ILLUMINA WAY, SAN DIEGO, CA, 92122, US
Illumina, Inc. reported revenue of 4.4B $ and net income of 853M $ over the last four quarters. Net margin is 19.42 %. Revenue changed by +1.29 % year over year. Earnings per share are 5.50 $. Market capitalisation is 40.5B $.
ILMN has a return on equity of 31.88 %, above the sector median of −41.68 %. Return on assets is 13.01 %, above the sector median of −32.11 %. Operating margin is 19.39 %, above the sector median of −26.84 %.
| 295M |
| TXG10x Genomics, Inc. | 80.65 | +4.36 % | 269M |
| BRKRBruker Corporation | 59.00 | +1.86 % | 137M |
| AVTRAvantor, Inc. | 15.67 | +1.82 % | 130M |
| BIOBio-Rad Laboratories, Inc. | 366.16 | +1.60 % | 98M |
| 271.61 |
| 293.69 |
| 4M |
| 02 October 2026 | 265.91 | 274.97 | 265.39 | 273.04 | 3M |
| 01 October 2026 | 273.22 | 274.03 | 264.79 | 265.72 | 2M |
| 30 September 2026 | 272.71 | 280.17 | 270.30 | 273.68 | 3M |
| 29 September 2026 | 273.10 | 278.99 | 267.00 | 272.00 | 2M |
| 28 September 2026 | 265.95 | 275.69 | 262.89 | 271.90 | 3M |
| 25 September 2026 | 272.16 | 276.97 | 267.66 | 270.00 | 5M |
| 24 September 2026 | 253.79 | 277.95 | 250.92 | 273.90 | 3M |
| 23 September 2026 | 248.79 | 256.17 | 247.00 | 255.38 | 2M |
| 22 September 2026 | 237.09 | 248.16 | 234.57 | 247.46 | 3M |
| 21 September 2026 | 241.51 | 248.31 | 238.26 | 238.82 | 3M |
| 18 September 2026 | 249.13 | 250.06 | 236.42 | 239.62 | 33M |
| 17 September 2026 | 233.85 | 246.76 | 232.99 | 245.18 | 4M |
| 16 September 2026 | 224.49 | 236.00 | 223.70 | 228.93 | 3M |
| 15 September 2026 | 208.95 | 226.76 | 207.90 | 222.29 | 3M |
| 14 September 2026 | 206.74 | 208.93 | 202.82 | 208.21 | 2M |
| 11 September 2026 | 201.81 | 208.39 | 200.01 | 206.45 | 2M |